Interferon Alpha (IFNA) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interferon Alpha (IFNA) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interferon Alpha (IFNA) - Pipeline Review, H2 2016', provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interferon Alpha (IFNA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA) 
- The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Interferon Alpha (IFNA) Overview 6
Therapeutics Development 7
Interferon Alpha (IFNA) - Products under Development by Stage of Development 7
Interferon Alpha (IFNA) - Products under Development by Therapy Area 8
Interferon Alpha (IFNA) - Products under Development by Indication 9
Interferon Alpha (IFNA) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interferon Alpha (IFNA) - Products under Development by Companies 12
Interferon Alpha (IFNA) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interferon Alpha (IFNA) - Companies Involved in Therapeutics Development 21
Argos Therapeutics Inc 21
Neovacs SA 22
PsiOxus Therapeutics Ltd 23
ZIOPHARM Oncology Inc 24
Interferon Alpha (IFNA) - Drug Profiles 25
AGS-009 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
NG-345 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
RTS-IFN Alpha - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Interferon Alpha (IFNA) - Dormant Projects 34
Interferon Alpha (IFNA) - Discontinued Products 35
Interferon Alpha (IFNA) - Featured News & Press Releases 36
Dec 07, 2016: Neovacs obtains FDA "Fast Track" designation for IFNa Kinoid in Lupus (SLE) 36
Nov 23, 2016: 3P Biopharmaceuticals signs production partnership with Neovacs 36
Nov 07, 2016: Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus 37
Oct 12, 2016: Neovacs signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris 37
Apr 28, 2016: Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States 38
Apr 14, 2016: Neovacs obtains South Korea health authority approval for IND application with IFNa kinoid in Lupus 38
Jan 06, 2016: Neovacs Secures 5 Million, from the Public Funding Program to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kino?d 39
Sep 24, 2015: Neovacs initiates phase IIb trial of IFNa-Kinoid for the treatment of lupus 39
Sep 17, 2015: Stellar Biotechnologies' Partner Neovacs Reports Potent and Long-Lasting Biological Activity of IFN-Alpha-Kinoid Immunotherapy 4 Years After Patient Dosing in Lupus Phase I/IIa Trial 40
Sep 09, 2015: Neovacs confirms potent and long-lasting biological activity of IFNa-Kinoid 4 years after patient dosing in phase I/IIa trial 40
Sep 01, 2015: Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus 41
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 42
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 43
May 13, 2015: Neovacs granted 1.8 million euros in research tax credit 44
Apr 01, 2015: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship 44

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Argos Therapeutics Inc, H2 2016 21
Pipeline by Neovacs SA, H2 2016 22
Pipeline by PsiOxus Therapeutics Ltd, H2 2016 23
Pipeline by ZIOPHARM Oncology Inc, H2 2016 24
Dormant Projects, H2 2016 34
Discontinued Products, H2 2016 35